NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1259.40 -1.50 (-0.12%)

1.2M NSE+BSE Volume

NSE 16 Jul, 2025 3:31 PM (IST)

105,107.2

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Dr. Reddy's Laboratories Ltd. is on 23 Jul 2025 for the purpose of Quarterly Results See details

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

08 Apr 2020

1259.40

-0.12%

Indian Pharma: Flight to Safety

Sell: Dr. Reddy's Laboratories Ltd.

Recommendation Target

HDFC Securities

The pharma sector is up ~1% YTD and has outperformed the Nifty Index by 28%. We prefer stocks with high India exposure as it offers greater earnings visibility, supported by reasonable valuations. Reiterate Buy on Cipla. Downgrade Dr. Reddy's to Reduce. Our positive stance on Indian pharma is premised on sectors relative resilience to Covid disruption, favorable currency tailwinds and stable outlook for India and US business. India growth has picked up (~10% growth for IPM as of MAT Mar20) and we forecast 11% growth for covered companies over the next two years. US pricing environment continues to remain benign and the regulatory challenges are well understood.

Geojit BNP Paribas released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1150.0 on 07 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

14 Feb 2020

1259.40

-0.12%

Dr Reddy's Laboratories

Hold: Dr. Reddy's Laboratories Ltd.

Target

ICICI Securities Limited

Revenues of the proposed acquired business were | 594 crore in FY19 and at | 377 crore for 9MFY20 (~| 500 crore on annualised basis). The implied valuation comes to ~3.8x annualised revenue. Going by the current trail, the valuation seems in line with industry standard but considering the growth trends of key brands, it is on the higher side. Nevertheless, this acquisition is in sync with the company's overall scheme of the things of being aggressive in branded formulations, especially in India and calibration in the US. Post this acquisition, the domestic business contribution in revenues is...

Dr. Reddy's Laboratories Ltd. is trading above its 200 day SMA of 1247.4

Dr. Reddy's Laboratories Ltd.

13 Feb 2020

1259.40

-0.12%

Dr. Reddy's Labs (Update): Wockhardt acquisition to be EPS accretive. Maintain NEUTRAL

Neutral: Dr. Reddy's Laboratories Ltd.

Recommendation Target

HDFC Securities

We have a Neutral rating and a TP of Rs 3,440 based on 20x FY22 EPS. With improved performance across geographies we believe the multiple is well justified. US accounts for 36% of revenues and the key products - gNuvaring and gCopaxone account for ~20% of our FY22 estimates. Despite factoring in these launches along with sustenance of good performance in non US markets and margin expansion as per company guidance, upside appears limited from current market price. Dr. Reddys announced acquisition of select brands of Wockhardt in India and other markets for Rs 18.5bn, which is ~3.7x FY20e sales (Rs 5bn annualised) and ~15x FY20e EV/EBIDTA. The deal adds scale (~17% of India revenues) and deepens Dr Reddys presence in the acute segment. The key 5 brands account for ~50%+ of the acquired portfolio. We expect Dr. Reddys to revive the growth (the acquired portfolio declined 15% yoy due to issues at Wockhardt) with improved serviceability of the products and increased sales & promotion. While we need to analyse the product portfolio in detail, our preliminary analysis suggests that the deal should be 1-2% EPS accretive in FY22. Maintain Neutral. TP of Rs 3,440/sh.

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

03 Feb 2020

1259.40

-0.12%

DR. REDDY'S LABORATARIES

Hold: Dr. Reddy's Laboratories Ltd.

Target

Geojit BNP Paribas

EBITDA increased 24.1% YoY, as EBITDA margin improved 200bps YoY to 23.5%. However, company reported a net loss of Rs. 538cr, impacted by impairment losses worth Rs. 1,320cr, arising from price erosion of...

Dr. Reddy's Laborato.. has an average target of 1321.50 from 8 brokers.

Dr. Reddy's Laboratories Ltd.

29 Jan 2020

1259.40

-0.12%

Dr. Reddy's Laboratories Ltd: Pharmaceuticals

Hold: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Karvy

Strong Revenue Growth Boost Operational Performance: Dr. Reddys Lab s (DRL) revenue, increased by 13.9% YoY to Rs. 43.8 Bn.

Dr. Reddy's Laboratories Ltd. is trading above its 200 day SMA of 1247.4

Dr. Reddy's Laboratories Ltd.

28 Jan 2020

1259.40

-0.12%

Result Review - DR Reddy

Hold: Dr. Reddy's Laboratories Ltd.

Hem Securities

Dr Reddy's Laboratories has been catering to the needs of the pharmaceutical sector for over two decades. Active Pharmaceutical Ingredients (API) are their core strength, having a wide range of portfolio. The company also manufactures generic medicines with business spread across India, Russia, US and Germany as well as Proprietary Products which includes NCE research, biologics business and differentiated formulations conducted in the US. Under this the...

Dr. Reddy's Laborato.. has an average target of 1321.50 from 8 brokers.

Dr. Reddy's Laboratories Ltd.

28 Jan 2020

1259.40

-0.12%

Dr Reddy's Laboratories

Hold: Dr. Reddy's Laboratories Ltd.

ICICI Securities Limited

US going through rough patch but promising launches ahead Despite challenging years, the US remains a key driver for the company, contributing ~42% to total revenues. The company has a strong pending pipeline comprising 99 ANDAs (53 Para IV filings, 32 FTFs) and two NDAs under 505 (b) (2) route. We expect US sales to grow at a CAGR of ~9% to...

Dr. Reddy's Laboratories Ltd. is trading above its 200 day SMA of 1247.4

Dr. Reddy's Laboratories Ltd.

27 Jan 2020

1259.40

-0.12%

Ex-US biz on track; Productivity improvement - the key focus

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

27 January 2020 The renewed strategy in the US, the enhanced focus on branded generics in emerging markets and the cost-control initiatives are promising steps that bolster DRRDs earnings prospects. We raise our EPS estimate by 7.3%/8.2%/9.2% for FY20/21/22 to factor in the better outlook in India/Russia, the higher gross margin and the scope of enhancing operating leverage. 3QFY20, driven by all business segments (except the US which grew moderately by 8% YoY to INR16b 36% of sales). Pharmaceutical Services and Active Ingredients (PSAI) segment (16% of sales) grew at 16% YoY to INR6.9b. India business (17% of sales) was up 13% YoY at INR7.6b, while Europe business (7% of sales) grew by 52% YoY. Emerging markets (21% of sales) was up 19% YoY to INR9.2b, led by CIS (+26% YoY) and Russia (+20% YoY). Gross margin expanded 20bp YoY (+260bp QoQ) to 54.1% on an improved product mix.

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

01 Dec 2019

1259.40

-0.12%

Ashika - Stock Picks - Dr. Reddy's Laboratories Ltd. - December 2019

Buy: Dr. Reddy's Laboratories Ltd.

Target

Ashika Research

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1306.2

Dr. Reddy's Laboratories Ltd.

12 Nov 2019

1259.40

-0.12%

DR. REDDY'S LABORATARIES

Hold: Dr. Reddy's Laboratories Ltd.

Geojit BNP Paribas

One-off gains lead to better than expected result Dr. Reddy's Laboratories is an Indian pharmaceutical manufacturer. The company is engaged in manufacturing and marketing of over 190...

Dr. Reddy's Laboratories Ltd. is trading above its 200 day SMA of 1247.4

Is Dr. Reddy's Laboratories Ltd. worth buying?

516 Votes:

Buy 78.29%

Sell 12.02%

Hold 9.69%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf